We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
John founded Fusion and was the driving force behind an oversubscribed series A financing
($46M USD), led by Johnson & Johnson Innovation–JJDC, Inc., closing in late 2017.
Under John’s leadership, and with the support of an international syndicate of investors and a
world-class executive team, Fusion has established itself as the leading targeted alpha therapy
company by combining a high value pipeline, proprietary linker technology, and innovative
partnering and supply chain strategies.
Fusion is a clinical stage-oncology company focused on developing novel targeted alpha
therapeutics (TATs) for the treatment of chemotherapy resistant cancers. Fusion's lead
product, FPX-1434, combines the precise targeting of a human experienced antibody with
Fusion’s linker technology and the alpha emitting cytotoxic isotope Actinium-225 to induce cancer
cell death. Fusion, which also has an exciting pipeline and internal R&D and clinical development
programs, has offices in Canada and the U.S.
This speaker's sessions: